Faron Pharmaceuticals Oy · LSE:FARN

Faron Pharmaceuticals Oy — Shareholder Meeting (May 2020)

25 slides from Faron Pharmaceuticals Oy's shareholder meeting presentation, May 18, 2020

1. Slide 1: Faron Pharmaceuticals AGM Presentation, 18 May 2020

   Faron Pharmaceuticals (LSE AIM: FARN, NASDAQ Helsinki: FARON) AGM Presentation, 18 May 2020 CEO Markku Jalkanen

2. Slide 2: # *)/ )/. *! /#$. +- . )//$*) #1 )*/ ) ++-*1 ) 0/#*-$.

   # *)/ )/. *! /#$. +- . )//$*) #1 )*/ ) ++-*1 4 ) 0/#*-$. + -.*) 2$/#$) /# ( )$)" *! /$*) *! /# $))$' -1$ . ) -& /. / . ( ) '$) *) /# *)/ )/. *! /#$. +- . )//$*) !*- /# +0-+*. *! )""$)" $) )4 $)1 ./( )/ /$1$/4 (4 3+*. ) $)$1$0' /* .$")$!$)/ -$.& *! '*.$)" '' *! /# +-*+ -/4 *- */# - .. /. $)1 ./ #$. +

3. Slide 3: Faron's pipeline is based on receptors involved in regulation of immune responses

   FARON’S PIPELINE IS BASED ON RECEPTORS INVOLVED IN THE REGULATION OF IMMUNE RESPONSES & VASCULAR DYSFUNCTIONS Immuno-Oncology ARDS & Organ protection Clevegen® Clever-1 regulates tissue immune status Traumakine® CD73 controls capillary leakage and escalation of inflammation AOC3 escalates inflammati

4. Slide 4: ! """#% !"#""#! "$'&! $! !$ '!"&$#*#$"$ +(!+%!"(!&0 04!&"*)&&&* &"%)& '!%'##$%%"!&" '!&(&"! $*$%'&%$" "!"!

   ! """#% !"#""#! "$'&! $! !$ '!"&$#*#$"$ +(!+%!"(!&0 04!&"*)&&&* &"%)& '!%'##$%%"!&" '!&(&"! $*$%'&%$" "!"! %/%&'*!%"&' "'$% %")$"&"! '! #"!&%+"0%& '&"! $$%!&(&"! $$%, "&!&"$-" !&"!$'!%!&$& !&. $&$%&"!"" !&"!&$& !&!$'"%&%+#&!&'$!!!$%!* (! %!)&"$&! "!%&$&#$" %!!!&0&' "'$&(&*! %($&' "'$&*#% #!!'%$' ! 1

5. Slide 5: ,.) .,#&)'*&.-1#."-1#."#(#''/(&&*,) #&-.)1,-#(,-#''/( .#0.#)()( #,'#((,*.#(.-(!)).)&,#&#.3.&&)-#(!&0&- 4 )1(,!/&.#)()…

   4 ,.) .,#&)'*&.-1#."-1#."#(#''/(&&*,) #&-.)1,-#(,-#''/( .#0.#)()( #,'#((,*.#(.-(!)).)&,#&#.3.&&)-#(!&0&- 4 )1(,!/&.#)() ,(!) '$),#("##.),3#''/("%*)#(.- . 4 #,-..,!.&-#)(,-*)(,-)-,0 ('&()' 4 .')(#.),#(!)''#..,)''(-,*#2*(-#)() #(.)#.#)(&./'),.3*- 4 #)&)!#--&..))'',#&-&'(/ ./,, 4 .,#&,-/&.-2*&#(3')&/&,

6. Slide 6: !:((*88+:11=7&.8*)A 2,7488A 23*99-74:,-8*;*7&1+:3)7&.8*8):7.3, 439.3:*)9.,-9(&8-2&3&,*2*39.394 &8-'&1&3(*4+A 243 *(*2…

   !:((*88+:11=7&.8*)A 2,7488A 23*99-74:,-8*;*7&1+:3)7&.8*8):7.3, 439.3:*)9.,-9(&8-2&3&,*2*39.394 &8-'&1&3(*4+A 243 *(*2'*7 A 2 5*7&9.3,14884+A 2 A 2 *9&88*984+A 243 *(*2'*7 A 2 *(*39A 2(7488*6:.9=74:3)<.11+.3&3(*9-*425&3=94 #41:39&7=8&1&7=&3)+**8&;.3,8'=4&7)&3)5*78433*1(439.3:*).394 !97:(9:7&1&1.,32*3

7. Slide 7: Turn on your immunity: Clevegen

   te Turn on your immunity F (cievecen

8. Slide 8: Macrophages as generals of anti-tumor immunity

   MACROPHAGES AS GENERALS OF ANTI-TUMOR IMMUNITY Pro-tumor (M2) Class Anti-tumor (M1) etching IL-10, TGFB 1L-12, TNFa Low MHCII High MHCII M2 macrophages are ... while M1 macrophages immunosuppressive... are immuno stimulatory Coss | cos [alee

9. Slide 9: Clevegen - the immune switch

   Cancer cell Only activation of adaptive immunity can fight cancer Clevegen - the QF immune switch « SN een - > Ye oe Cancer cell

10. Slide 10: !# !# 0"1 !# ( " !# ( " =54 ""# ##8 8"'" "'"

    !# !# 0"1 !# ( " !# ( " =54 ""# ##8 8"'" "'" =54 =6#"' =6#"' ##=: ##=: =54 + + + + + + =54 + + 2=54 2 0<64."'1 =9#"' =54 =5; <4,5."' ##=74 =6#"' ' #=56 =54 "#! =54 0<1=54 0<1 #) !#"$ !#( " &!!#) $) ! # 8-645:/ 5-6464 5-6464/ 7-6465 8-6464/ 6-6467 54

11. Slide 11: ! #& /& 3& -++6 -++6 -++6 6/7-07'6 ,0+6 ,0+6 ,0+6 ,++6 ,++6 ,++6

    ! #& /& 3& -++6 -++6 -++6 6/7-07'6 6 6 ,0+6 ,0+6 ,0+6 ,++6 ,++6 ,++6 ( 0+6 0+6 0+6 +6 +6 +6 ,- ,,0 - . / ,- ,,0 - . / ,- ,,0 - . / ,-2!%" . ,-2! / 3 3%/ & & ,/+6 .++6 .++6 ,-+6 -0+6 -0+6 6 6 6 ,++6 -++6 -++6 3+6 ,0+6 ,0+6 1+6 /+6 ,++6 ,++6 -+6 0+6 0+6 +6 +6 +6 ,- ,,0 - . / ,- ,,0 - . / ,- ,,0 - . /

12. Slide 12: & &- ! ) 3,%,0 )) 3,%,- ))) 3,%,,- $ ' & &-# &-#

    & &- ! ) 3,%,0 )) 3,%,- ))) 3,%,,- $ ' & &-# &-# &/#%( # "# &% &% " .,-1!+-02 -.

13. Slide 13: Increasing number of responding cancers

    INCREASING NUMBER OF RESPONDING CANCERS Colorectal cancer Cutaneous melanoma 6 weeks Note the clearance of pleural effusion Arrows point shrinking lung metastasis (red circle). Treatment initiated after in MSI low CRC patient. Treatment four lines of therapy including initiated after six lines of th

14. Slide 14: $ .* +& *,'/(+ *-(+ - )!*/(+%"$ ) 1* +(#% ! $" * +!

    $ .* +& *,'/(+ *-(+ - )!*/(+%"$ ) 1* +(#% ! $" * +! -0

15. Slide 15: "! "! 1!" !" # "' !. / " ! "' ! .!" /

    "! "! 1!" !" # "' !. / " ! "' ! .!" / !" ! , * !" " "* 7 - ! 7 -1305!1!" !1!" 1305!1!" ! ,"! ! " !"'! !" " ! "' ! " ! "' ! "! 2016 2020 2021 2023 2024 2025 ("#"!!"!"' ! )"( 7" ""#! ("" !"'' !1!"!%! !"*" "*!!"! #!"'! '* " .!/!#!" * ! " 15

16. Slide 16: $!!"- "" !"" %##!%$"$!""!$#$$!" "!###!%"#$ -3"!# "## !!""'4 !. -4/ 0 &""&"! "!.,,)'"!" )#"#!

    $!!"- "" !"" %##!%$"$!""!$#$$!" 0 "!###!%"#$ -3"!# "## !!""'4 !. -4/ 0 &""&"! "!.,,)'"!" )#"#! ")"/)!# "' "#!"'" &"#!##"$""$" $"'!%!)-"#%'#"(!" o % !:8? !. 3/ !428? !. 4/ "% !#$# %" !!$ !# $$#".",)",, ,,4238+39+542/ !*** o !$ -3!"$ !!!!"%" !# $$ " . ! "," 4234*353.6/+:86-95/ &"#!#%!)-"#%!##$#"* !#'

17. Slide 17: ) ' "#$("#" $! !!# !#' "" ) !#' "!#"##&# ) !$#!( " %!

    ) ' "#$("#" $! !!# !#' "" ) !#' "!#"##&# ) !$#!( " %! #&( ) (!!#!$ ! "##$" ) #$ !#!"$""" ) '$#$#$!' "

18. Slide 18: Traumakine

    TRAUMAKINE

19. Slide 19: ) * !%!!##'$() $)" "")!#!$ !%""%!# "!" $!" ( &$$!' " %!633)333""$'0) 6&!&+ !##'63.73?5

    ) * !%!!##'$() $)" "")!#!$ !%""%!# "!" $!" ( &$$!' " %!633)333""$'0) 6&!&+ !##'63.73?5 %! ##" "58 '"#7:'"# " #5 "$#"#6,9" #'" '!#6)7 :3.433?"$!!#% !##" #"!8 '7;?!#!#$!&!#!4 '!7 4/ #, 5349)5/%# #, 534:) 6/ $ #, 5338)7/!! #, 5344*697+45<6-637) 8/!! #, 5349*75+:58-6; 4<

20. Slide 20: Survival (%)

    ( %$ #$)" 6<$ 5:)#*## ")##$'" %!# %!' !!!%- 100 "+!!)7/1& ..* !!%26 75 A4,45/6<)0 !"& !!!!)703& ./* (! $ ! Survival (%) !!%/.6 "!!!%$! 50 !# %! 25 Untreated Treated p=0·01 A4,45 0 0 5 10 15 20 25 30 !% " !# %! $"" $*# #$)!" " %#'$ "$$)$#( $#'# '"$(!$ !$$#' "' !" &$%%$ %$ ####$# !$$ "$ ##$# '$!" &$%%

21. Slide 21: - .* / $##!)$)4+4!() .$! #!4)5 =523-496". ,3423,( 32) ##" <4;'!" .$" .$" !!(

    - .* / $##!)$)4+4!() .$! #!4)5 =523-496". ,3423,( 32) ##" <4;'!" .$" .$" !!( ! $! % " (""* #* !##' !##' ! ' .$" .$" !##'0 !##'0 %## !9'" '" '" !#! "%! 2 48 92 382 562 !#&!$ " . !+#%%" !##'&$# $&#$#! "#'"""$"#"####"#!$"" #!!##%#'!""!##'!"(7' "#'""""$"#"##!$ #% &#$###$""#!"-48!##(32+6<.-" '#". 4/#!",%

22. Slide 22: IFN beta-1a treatment arm

    IFN beta-1a treatment arm Glucocorticoids on D0– D6 !!

23. Slide 23: 3//.02 &+.! +0$1/.-1$5(2'0 3, *(-$ / 02("(/ 2(.-(- -# 20( +1 9 (- +(1$-$5123#7/+

    9 3//.02 &+.! +0$1/.-1$5(2'0 3, *(-$ / 02("(/ 2(.-(- -# 20( +1 9 (- +(1$-$5123#7/+ -%.0/.12 ""$/2 -"$.%123#7#$1(&- -#/0.2.".+ 9 23#7(-(2( 2(.-/.12$62$0- +%3-#(-& 9 .-2(-3$(-2$0 "2(.-15(2'*$7./(-(.-+$ #$012.,(-(,(8$".02(".12$0.(#31$(- / 2($-21 '$.,/ -7-.2$# 0$".,,$-# 2(.-, #$!7(- -3 07 2' 212$0.(#11'

24. Slide 24: ' "#!$ #$%2 2$$& !2! !!*"#!#,' ,(""#$%!#%'%% &$&".!*# & $*$% $%& !$&""#$$'%&!#$ 1046382.'$(#(!!, '

    4 ' "#!$ #$%2 2$$& !2! !!*"#!#,' ,(""#$%!#%'%% &$&".!*# & $*$% $%& !$&""#$$'%&!#$ 1046382.'$(#(!!, ' %#%$ 2:"!$%'&!#2$$!% #!"$4 $5 ! '#%$* &'(0#0!'' & !$&""#$$' ;#!"$%!& $%&% :#!"$ 5 $%&*$%#$%2 2& !" $1 %#(% "%'$ %! ##(!#!&$&'' '$%%%$%* *!' $%%$%%!# !"#$!%&!#$ ($(.(+!!#( !!%!#%*%!$ '$(%!&%!$% %!)%*,

25. Slide 25: Thank You

    ” FARON Thank You “Our world is built on biology. Once we begin to understand our biology, it then becomes a technology

Faron Pharmaceuticals — Shareholder Meeting (May 2020) on 6ix